Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 3Enrolling by invitation 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 92Recurrence 11Neoplasms, Plasma Cell 9Lymphoma 8Lymphoma, Mantle-Cell 6Waldenstrom Macroglobulinemia 5Smoldering Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Hodgkin Disease 2Hematologic Neoplasms 2Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1

Interventions

Dexamethasone 14Lenalidomide 13Calcium Dobesilate 7carfilzomib 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Melphalan 3Leflunomide 3Curcumin 3isatuximab 2iberdomide 2daratumumab 2Denosumab 2Cyclophosphamide 2Bortezomib 2selinexor 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1elotuzumab 1citarinostat 1atezolizumab 1Urination 1Transplantation, Autologous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Smoldering Multiple Myeloma × carfilzomib × Clear all
NCT03289299 2023-12-12

ASCENT

International Myeloma Foundation

Phase 2 Active not recruiting
87 enrolled
Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT03673826 2023-11-01

HO147SMM

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 2 Active not recruiting
58 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT02415413 2022-09-10

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

PETHEMA Foundation

Phase 2 Active not recruiting
90 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT03815279 2019-08-16

iStopMM

Landspitali University Hospital

Phase 2 Enrolling by invitation
80 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡